Eagle Pharmaceuticals Reiterates Its Previously Issued Guidance For Fy23, With Adjusted EBITDA Of $78M-$84M And Adjusted EPS Of $4.40-$4.70 Versus Consensus Of $4.34
Portfolio Pulse from Benzinga Newsdesk
Eagle Pharmaceuticals has reiterated its previously issued guidance for FY23, with an adjusted EBITDA of $78M-$84M and adjusted EPS of $4.40-$4.70, which is higher than the consensus of $4.34.
August 17, 2023 | 10:53 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Eagle Pharmaceuticals' reiteration of its FY23 guidance, which surpasses the consensus, could potentially boost investor confidence and positively impact its stock price.
Eagle Pharmaceuticals' reiteration of its FY23 guidance, which is higher than the consensus, indicates strong financial performance. This could boost investor confidence and lead to an increase in demand for its stock, thereby potentially driving up its price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100